Cargando…

Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release

[Image: see text] Conjugation of therapeutic payloads to biologics including antibodies and albumin can enhance the selectively of drug delivery to solid tumors. However, achieving activity in tumors while avoiding healthy tissues remains a challenge, and payload activity in off-target tissues can c...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintana, Jeremy M., Arboleda, David, Hu, Huiyu, Scott, Ella, Luthria, Gaurav, Pai, Sara, Parangi, Sareh, Weissleder, Ralph, Miller, Miles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390333/
https://www.ncbi.nlm.nih.gov/pubmed/35833631
http://dx.doi.org/10.1021/acs.bioconjchem.2c00174
Descripción
Sumario:[Image: see text] Conjugation of therapeutic payloads to biologics including antibodies and albumin can enhance the selectively of drug delivery to solid tumors. However, achieving activity in tumors while avoiding healthy tissues remains a challenge, and payload activity in off-target tissues can cause toxicity for many such drug-conjugates. Here, we address this issue by presenting a drug–conjugate linker strategy that releases an active therapeutic payload upon exposure to ionizing radiation. Localized X-ray irradiation at clinically relevant doses (8 Gy) yields 50% drug (doxorubicin or monomethyl auristatin E, MMAE) release under hypoxic conditions that are traditionally associated with radiotherapy resistance. As proof-of-principle, we apply the approach to antibody– and albumin–drug conjugates and achieve >2000-fold enhanced MMAE cytotoxicity upon irradiation. Overall, this work establishes ionizing radiation as a strategy for spatially localized cancer drug delivery.